Welcome to our dedicated page for Rigel Pharmaceuticals (New) news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals (New) stock.
Rigel Pharmaceuticals reports news on a commercial-stage biotechnology business focused on hematologic disorders and cancer. Company updates commonly cover sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), along with contract revenue from collaborations and quarterly operating results.
Recurring developments also include clinical and regulatory updates for Rigel's pipeline, including R289 in lower-risk MDS, published clinical data involving GAVRETO, licensing and collaboration activity, board appointments, equity inducement grants and other governance matters tied to its Nasdaq-listed common stock.
Rigel Pharmaceuticals announces significant presentations at the upcoming 2024 ASCO and EHA Hybrid Congresses, showcasing the efficacy of their lead products, REZLIDHIA (olutasidenib) for mIDH1 AML and TAVALISSE (fostamatinib) for chronic immune thrombocytopenia (ITP).
The final five-year results from the Phase 2 trial highlight REZLIDHIA's durable responses in heavily pretreated mIDH1 AML patients. Further, REZLIDHIA proves effective in elderly, transplant-eligible, and post-MPN patients.
Additionally, data from a Phase 1b trial of R2891, an IRAK1/4 inhibitor for lower-risk myelodysplastic syndrome (LR-MDS), and real-world analyses of TAVALISSE for ITP will be presented.
These results underscore Rigel's robust hematology and oncology portfolio, promising significant benefits for patients with challenging conditions.
Rigel Pharmaceuticals, Inc. reported total revenue of $29.5 million for the first quarter of 2024, driven by strong commercial demand for TAVALISSE® and REZLIDHIA®. The company acquired GAVRETO®, a U.S. marketed product for lung and thyroid cancer, expanded its portfolio, and appointed a new Chief Medical Officer. Rigel is progressing clinical trials, collaborating with MD Anderson and CONNECT, and advancing pipeline programs. Financially, total revenue included $21.1 million from TAVALISSE sales, $4.9 million from REZLIDHIA sales, and $3.5 million from collaborations. The net loss was $8.2 million. Rigel had $49.6 million in cash and investments as of March 31, 2024.
Rigel Pharmaceuticals, Inc. will report its first quarter 2024 financial results on May 7, 2024, followed by a conference call and webcast discussing financial results and business updates. Rigel Pharmaceuticals is focused on developing therapies for hematologic disorders and cancer.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.